{
  "resourceType": "Bundle",
  "id": "core-meds-diabetes-bundle",
  "meta": {
    "profile": ["https://lattice.one/fhir/StructureDefinition/variable-pack-bundle"]
  },
  "type": "collection",
  "timestamp": "2024-01-19T00:00:00Z",
  "entry": [
    {
      "fullUrl": "urn:uuid:atc-A10BA",
      "resource": {
        "resourceType": "Basic",
        "id": "atc-A10BA",
        "meta": {
          "profile": ["https://lattice.one/fhir/StructureDefinition/variable-definition"]
        },
        "code": {
          "coding": [
            {
              "system": "https://lattice.one/fhir/CodeSystem/resource-types",
              "code": "variable-definition",
              "display": "Variable Definition"
            }
          ]
        },
        "extension": [
          {
            "url": "https://lattice.one/fhir/ext/variable-code",
            "valueString": "A10BA"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-code-system",
            "valueString": "http://www.whocc.no/atc"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-display",
            "valueString": "Metformin"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-description",
            "valueString": "Biguanides - metformin"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-data-type",
            "valueString": "boolean"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-category",
            "valueString": "oral-hypoglycemic"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-clinical-note",
            "valueString": "First-line for T2DM. Hold if eGFR <30 or acute illness. Contraindicated in lactic acidosis risk."
          }
        ]
      }
    },
    {
      "fullUrl": "urn:uuid:atc-A10BB",
      "resource": {
        "resourceType": "Basic",
        "id": "atc-A10BB",
        "meta": {
          "profile": ["https://lattice.one/fhir/StructureDefinition/variable-definition"]
        },
        "code": {
          "coding": [
            {
              "system": "https://lattice.one/fhir/CodeSystem/resource-types",
              "code": "variable-definition",
              "display": "Variable Definition"
            }
          ]
        },
        "extension": [
          {
            "url": "https://lattice.one/fhir/ext/variable-code",
            "valueString": "A10BB"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-code-system",
            "valueString": "http://www.whocc.no/atc"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-display",
            "valueString": "Sulfonylurea"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-description",
            "valueString": "Sulfonylureas - e.g., glipizide, gliclazide, glimepiride, glyburide"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-data-type",
            "valueString": "boolean"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-category",
            "valueString": "oral-hypoglycemic"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-clinical-note",
            "valueString": "Hypoglycemia risk, especially in elderly and CKD. Gliclazide preferred in renal impairment."
          }
        ]
      }
    },
    {
      "fullUrl": "urn:uuid:atc-A10BH",
      "resource": {
        "resourceType": "Basic",
        "id": "atc-A10BH",
        "meta": {
          "profile": ["https://lattice.one/fhir/StructureDefinition/variable-definition"]
        },
        "code": {
          "coding": [
            {
              "system": "https://lattice.one/fhir/CodeSystem/resource-types",
              "code": "variable-definition",
              "display": "Variable Definition"
            }
          ]
        },
        "extension": [
          {
            "url": "https://lattice.one/fhir/ext/variable-code",
            "valueString": "A10BH"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-code-system",
            "valueString": "http://www.whocc.no/atc"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-display",
            "valueString": "DPP-4 Inhibitor"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-description",
            "valueString": "Dipeptidyl peptidase-4 inhibitors - e.g., sitagliptin, saxagliptin, linagliptin, alogliptin"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-data-type",
            "valueString": "boolean"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-category",
            "valueString": "oral-hypoglycemic"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-clinical-note",
            "valueString": "Weight-neutral, low hypoglycemia risk. Linagliptin no dose adjustment in CKD."
          }
        ]
      }
    },
    {
      "fullUrl": "urn:uuid:atc-A10BJ",
      "resource": {
        "resourceType": "Basic",
        "id": "atc-A10BJ",
        "meta": {
          "profile": ["https://lattice.one/fhir/StructureDefinition/variable-definition"]
        },
        "code": {
          "coding": [
            {
              "system": "https://lattice.one/fhir/CodeSystem/resource-types",
              "code": "variable-definition",
              "display": "Variable Definition"
            }
          ]
        },
        "extension": [
          {
            "url": "https://lattice.one/fhir/ext/variable-code",
            "valueString": "A10BJ"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-code-system",
            "valueString": "http://www.whocc.no/atc"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-display",
            "valueString": "GLP-1 Receptor Agonist"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-description",
            "valueString": "GLP-1 receptor agonists - e.g., semaglutide, liraglutide, dulaglutide, exenatide"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-data-type",
            "valueString": "boolean"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-category",
            "valueString": "injectable-non-insulin"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-clinical-note",
            "valueString": "CV benefit (semaglutide, liraglutide, dulaglutide). Weight loss. GI side effects common initially."
          }
        ]
      }
    },
    {
      "fullUrl": "urn:uuid:atc-A10BK",
      "resource": {
        "resourceType": "Basic",
        "id": "atc-A10BK",
        "meta": {
          "profile": ["https://lattice.one/fhir/StructureDefinition/variable-definition"]
        },
        "code": {
          "coding": [
            {
              "system": "https://lattice.one/fhir/CodeSystem/resource-types",
              "code": "variable-definition",
              "display": "Variable Definition"
            }
          ]
        },
        "extension": [
          {
            "url": "https://lattice.one/fhir/ext/variable-code",
            "valueString": "A10BK"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-code-system",
            "valueString": "http://www.whocc.no/atc"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-display",
            "valueString": "SGLT2 Inhibitor"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-description",
            "valueString": "Sodium-glucose co-transporter 2 inhibitors - e.g., empagliflozin, dapagliflozin, canagliflozin"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-data-type",
            "valueString": "boolean"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-category",
            "valueString": "oral-hypoglycemic"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-clinical-note",
            "valueString": "CV and renal benefits independent of diabetes. First-line add-on with CKD, HF, or ASCVD. DKA risk."
          }
        ]
      }
    },
    {
      "fullUrl": "urn:uuid:atc-A10BG",
      "resource": {
        "resourceType": "Basic",
        "id": "atc-A10BG",
        "meta": {
          "profile": ["https://lattice.one/fhir/StructureDefinition/variable-definition"]
        },
        "code": {
          "coding": [
            {
              "system": "https://lattice.one/fhir/CodeSystem/resource-types",
              "code": "variable-definition",
              "display": "Variable Definition"
            }
          ]
        },
        "extension": [
          {
            "url": "https://lattice.one/fhir/ext/variable-code",
            "valueString": "A10BG"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-code-system",
            "valueString": "http://www.whocc.no/atc"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-display",
            "valueString": "Thiazolidinedione (TZD)"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-description",
            "valueString": "Thiazolidinediones - pioglitazone, rosiglitazone"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-data-type",
            "valueString": "boolean"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-category",
            "valueString": "oral-hypoglycemic"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-clinical-note",
            "valueString": "Contraindicated in heart failure. Fluid retention, weight gain, fracture risk."
          }
        ]
      }
    },
    {
      "fullUrl": "urn:uuid:atc-A10BF",
      "resource": {
        "resourceType": "Basic",
        "id": "atc-A10BF",
        "meta": {
          "profile": ["https://lattice.one/fhir/StructureDefinition/variable-definition"]
        },
        "code": {
          "coding": [
            {
              "system": "https://lattice.one/fhir/CodeSystem/resource-types",
              "code": "variable-definition",
              "display": "Variable Definition"
            }
          ]
        },
        "extension": [
          {
            "url": "https://lattice.one/fhir/ext/variable-code",
            "valueString": "A10BF"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-code-system",
            "valueString": "http://www.whocc.no/atc"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-display",
            "valueString": "Alpha-Glucosidase Inhibitor"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-description",
            "valueString": "Alpha-glucosidase inhibitors - acarbose, miglitol, voglibose"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-data-type",
            "valueString": "boolean"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-category",
            "valueString": "oral-hypoglycemic"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-clinical-note",
            "valueString": "Targets postprandial glucose. GI side effects limit use. Take with first bite of meal."
          }
        ]
      }
    },
    {
      "fullUrl": "urn:uuid:atc-A10BX",
      "resource": {
        "resourceType": "Basic",
        "id": "atc-A10BX",
        "meta": {
          "profile": ["https://lattice.one/fhir/StructureDefinition/variable-definition"]
        },
        "code": {
          "coding": [
            {
              "system": "https://lattice.one/fhir/CodeSystem/resource-types",
              "code": "variable-definition",
              "display": "Variable Definition"
            }
          ]
        },
        "extension": [
          {
            "url": "https://lattice.one/fhir/ext/variable-code",
            "valueString": "A10BX"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-code-system",
            "valueString": "http://www.whocc.no/atc"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-display",
            "valueString": "Meglitinide"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-description",
            "valueString": "Meglitinides/glinides - repaglinide, nateglinide"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-data-type",
            "valueString": "boolean"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-category",
            "valueString": "oral-hypoglycemic"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-clinical-note",
            "valueString": "Short-acting insulin secretagogue. Flexible dosing with meals. Hypoglycemia risk."
          }
        ]
      }
    },
    {
      "fullUrl": "urn:uuid:atc-A10A",
      "resource": {
        "resourceType": "Basic",
        "id": "atc-A10A",
        "meta": {
          "profile": ["https://lattice.one/fhir/StructureDefinition/variable-definition"]
        },
        "code": {
          "coding": [
            {
              "system": "https://lattice.one/fhir/CodeSystem/resource-types",
              "code": "variable-definition",
              "display": "Variable Definition"
            }
          ]
        },
        "extension": [
          {
            "url": "https://lattice.one/fhir/ext/variable-code",
            "valueString": "A10A"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-code-system",
            "valueString": "http://www.whocc.no/atc"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-display",
            "valueString": "Insulin (Any)"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-description",
            "valueString": "Any insulin preparation - includes all types and combinations"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-data-type",
            "valueString": "boolean"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-category",
            "valueString": "insulin"
          }
        ]
      }
    },
    {
      "fullUrl": "urn:uuid:atc-A10AB",
      "resource": {
        "resourceType": "Basic",
        "id": "atc-A10AB",
        "meta": {
          "profile": ["https://lattice.one/fhir/StructureDefinition/variable-definition"]
        },
        "code": {
          "coding": [
            {
              "system": "https://lattice.one/fhir/CodeSystem/resource-types",
              "code": "variable-definition",
              "display": "Variable Definition"
            }
          ]
        },
        "extension": [
          {
            "url": "https://lattice.one/fhir/ext/variable-code",
            "valueString": "A10AB"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-code-system",
            "valueString": "http://www.whocc.no/atc"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-display",
            "valueString": "Rapid-Acting Insulin"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-description",
            "valueString": "Fast-acting insulins - e.g., insulin lispro, aspart, glulisine"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-data-type",
            "valueString": "boolean"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-category",
            "valueString": "insulin"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-clinical-note",
            "valueString": "Prandial/bolus insulin. Onset 15 min, duration 3-5 hours. Give with meals."
          }
        ]
      }
    },
    {
      "fullUrl": "urn:uuid:atc-A10AC",
      "resource": {
        "resourceType": "Basic",
        "id": "atc-A10AC",
        "meta": {
          "profile": ["https://lattice.one/fhir/StructureDefinition/variable-definition"]
        },
        "code": {
          "coding": [
            {
              "system": "https://lattice.one/fhir/CodeSystem/resource-types",
              "code": "variable-definition",
              "display": "Variable Definition"
            }
          ]
        },
        "extension": [
          {
            "url": "https://lattice.one/fhir/ext/variable-code",
            "valueString": "A10AC"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-code-system",
            "valueString": "http://www.whocc.no/atc"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-display",
            "valueString": "Intermediate-Acting Insulin"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-description",
            "valueString": "Intermediate-acting insulins - NPH insulin (isophane)"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-data-type",
            "valueString": "boolean"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-category",
            "valueString": "insulin"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-clinical-note",
            "valueString": "NPH duration 12-18 hours. Peak at 4-8 hours - nocturnal hypoglycemia risk."
          }
        ]
      }
    },
    {
      "fullUrl": "urn:uuid:atc-A10AD",
      "resource": {
        "resourceType": "Basic",
        "id": "atc-A10AD",
        "meta": {
          "profile": ["https://lattice.one/fhir/StructureDefinition/variable-definition"]
        },
        "code": {
          "coding": [
            {
              "system": "https://lattice.one/fhir/CodeSystem/resource-types",
              "code": "variable-definition",
              "display": "Variable Definition"
            }
          ]
        },
        "extension": [
          {
            "url": "https://lattice.one/fhir/ext/variable-code",
            "valueString": "A10AD"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-code-system",
            "valueString": "http://www.whocc.no/atc"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-display",
            "valueString": "Premixed Insulin"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-description",
            "valueString": "Premixed insulin combinations - e.g., 70/30, 75/25, 50/50 mixes"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-data-type",
            "valueString": "boolean"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-category",
            "valueString": "insulin"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-clinical-note",
            "valueString": "Convenient but less flexible dosing. Typically BID with meals."
          }
        ]
      }
    },
    {
      "fullUrl": "urn:uuid:atc-A10AE",
      "resource": {
        "resourceType": "Basic",
        "id": "atc-A10AE",
        "meta": {
          "profile": ["https://lattice.one/fhir/StructureDefinition/variable-definition"]
        },
        "code": {
          "coding": [
            {
              "system": "https://lattice.one/fhir/CodeSystem/resource-types",
              "code": "variable-definition",
              "display": "Variable Definition"
            }
          ]
        },
        "extension": [
          {
            "url": "https://lattice.one/fhir/ext/variable-code",
            "valueString": "A10AE"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-code-system",
            "valueString": "http://www.whocc.no/atc"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-display",
            "valueString": "Long-Acting Insulin"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-description",
            "valueString": "Long-acting/basal insulins - e.g., glargine, detemir, degludec"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-data-type",
            "valueString": "boolean"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-category",
            "valueString": "insulin"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-clinical-note",
            "valueString": "Basal insulin for fasting glucose control. Glargine U300 and degludec have longer duration, less hypoglycemia."
          }
        ]
      }
    },
    {
      "fullUrl": "urn:uuid:atc-A10BD",
      "resource": {
        "resourceType": "Basic",
        "id": "atc-A10BD",
        "meta": {
          "profile": ["https://lattice.one/fhir/StructureDefinition/variable-definition"]
        },
        "code": {
          "coding": [
            {
              "system": "https://lattice.one/fhir/CodeSystem/resource-types",
              "code": "variable-definition",
              "display": "Variable Definition"
            }
          ]
        },
        "extension": [
          {
            "url": "https://lattice.one/fhir/ext/variable-code",
            "valueString": "A10BD"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-code-system",
            "valueString": "http://www.whocc.no/atc"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-display",
            "valueString": "Oral Hypoglycemic Combination"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-description",
            "valueString": "Fixed-dose oral antidiabetic combinations - e.g., metformin/sitagliptin, metformin/empagliflozin"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-data-type",
            "valueString": "boolean"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-category",
            "valueString": "oral-hypoglycemic"
          },
          {
            "url": "https://lattice.one/fhir/ext/variable-clinical-note",
            "valueString": "Improves adherence with single pill. Check individual component contraindications."
          }
        ]
      }
    }
  ]
}
